Cysteinyl leukotrienes synthesis is involved in aristolochic acid I-induced apoptosis in renal proximal tubular epithelial cells

Toxicology

Volumn 287, Issue 1-3, 2011, Pages 38-45

  Yang, Hongyu ^a   Dou, Yuan ^a   Zheng, Xuehua ^a   Tan, Yun ^a   Cheng, Jiajun ^a   Li, Lu ^a   Du, Yue ^a   Zhu, Danyan ^a   Lou, Yijia ^a  

^a ZHEJIANG UNIVERSITY   (China)

Author keywords

Apoptosis; Aristolochic acid I; Cysteinyl leukotrienes; ERK activation; LLC PK1 cell line; MAPEG

Indexed keywords

1,4 DIAMINO 1,4 BIS(2 AMINOPHENYLTHIO) 2,3 DICYANOBUTADIENE; ARACHIDONATE 5 LIPOXYGENASE ACTIVATING PROTEIN; ARACHIDONATE 5 LIPOXYGENASE ACTIVATING PROTEIN INHIBITOR; ARISTOLOCHIC ACID; ARISTOLOCHIC ACID I; CASPASE 3; CYTOCHROME C; CYTOTOXIC AGENT; GLUTATHIONE TRANSFERASE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE P38; MK 866; PEPTIDOLEUKOTRIENE; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CONTROLLED STUDY; ENZYME RELEASE; ENZYME SYNTHESIS; EPITHELIUM CELL; KIDNEY CELL; KIDNEY PROXIMAL TUBULE; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ANIMALS; APOPTOSIS; ARISTOLOCHIC ACIDS; BUTADIENES; CYSTEINE; DOSE-RESPONSE RELATIONSHIP, DRUG; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; INDOLES; KIDNEY TUBULES, PROXIMAL; LEUKOTRIENES; LLC-PK1 CELLS; NITRILES; PHOSPHORYLATION; SWINE;

EID: 79960697705     PISSN: 0300483X     EISSN: 18793185     Source Type: Journal    
DOI: 10.1016/j.tox.2011.05.014     Document Type: Article

References (44)

1. Assem E.S., Abdullah N.A. Release of thromboxane B2 and leukotriene C4 and reduction in renal perfusion in experimental anaphylactic reaction of isolated guinea pig kidney. Int. Arch. Allergy Appl. Immunol. 1987, 82:212-214.
2. Badr K.F., Baylis C., Pfeffer J.M., Pfeffer M.A., Soberman R.J., Lewis R.A., Austen K.F., Corey E.J., Brenner B.M. Renal and systemic hemodynamic responses to intravenous infusion of leukotriene C4 in the rat. Circ. Res. 1984, 54:492-499.
3. Bartfeld H. Immunological studies demonstrating the enhancing effect of aristolochic acid on immunoreactions (author's translation). Arzneimittelforschung 1977, 27:2297-2298.
4. Berger W., De Chandt M.T., Cairns C.B. Zileuton: clinical implications of 5-Lipoxygenase inhibition in severe airway disease. Int. J. Clin. Pract. 2007, 61:663-676.
5. Chen M., Su M., Zhao L., Jiang J., Liu P., Cheng J., Lai Y., Liu Y., Jia W. Metabonomic study of aristolochic acid-induced nephrotoxicity in rats. J. Proteome Res. 2006, 5:995-1002.
6. Deufel J., Ganshirt H. Studies on the effect of aristolochic acid on bacteria and cell division of Vicia faba L. Pharmazie 1953, 8:679-682.
7. Ejaz P., Bhojani K., Joshi V.R. NSAIDs and kidney. J. Assoc. Physicians India 2004, 52:632-640.
8. Filitis L.N., Massagetov P.S. On the antineoplastic activity of aristolochic acid. Vopr Onkol. 1961, 7(8):97-98.
9. Funk C.D. Prostaglandins and leukotrienes: advances in eicosanoid biology. Science 2001, 294:1871-1875.
10. Gardiner J., Andreeva Z., Barton D., Ritchie A., Overall R., Marc J. The phospholipase A inhibitor, aristolochic acid, disrupts cortical microtubule arrays and root growth in Arabidopsis. Plant Biol. (Stuttg) 2008, 10:725-731.
11. Garrington T.P., Johnson G.L. Organization and regulation of mitogen-activated protein kinase signaling pathways. Curr. Opin. Cell Biol. 1999, 11:211-218.
12. Hebert H., Jegerschold C. The structure of membrane associated proteins in eicosanoid and glutathione metabolism as determined by electron crystallography. Curr. Opin. Struct. Biol. 2007, 17:396-404.
13. Hong Y.T., Fu L.S., Chung L.H., Hung S.C., Huang Y.T., Chi C.S. Fanconi's syndrome, interstitial fibrosis and renal failure by aristolochic acid in Chinese herbs. Pediatr. Nephrol. 2006, 21:577-579.
14. Hsin Y.H., Cheng C.H., Tzen J.T., Wu M.J., Shu K.H., Chen H.C. Effect of aristolochic acid on intracellular calcium concentration and its links with apoptosis in renal tubular cells. Apoptosis 2006, 11:2167-2177.
15. Huljic S., Bruske E.I., Pfitzenmaier N., O'Brien E., Dietrich D.R. Species-specific toxicity of aristolochic acid (AA) in vitro. Toxicol. In Vitro 2008, 22:1213-1221.
16. Jakobsson P.J., Morgenstern R., Mancini J., Ford-Hutchinson A., Persson B. Membrane-associated proteins in eicosanoid and glutathione metabolism (MAPEG). A widespread protein superfamily. Am. J. Respir. Crit. Care Med. 2000, 161:S20-S24.
17. Jummel F. On the efficacy of aristolochic acid on chronic inflammatory tissue processes. Ther. Ggw. 1964, 103:1020-1022.
18. Koh S.H., Noh M.Y., Kim S.H. Amyloid-beta-induced neurotoxicity is reduced by inhibition of glycogen synthase kinase-3. Brain Res. 2008, 1188:254-262.
19. Kupchan S.M., Doskotch R.W. Tumor inhibitors. I. Aristolochic acid, the active principle of Aristolochia Indica. J. Med. Pharm. Chem. 1962, 91:657-659.
20. Lebeau C., Debelle F.D., Arlt V.M., Pozdzik A., De Prez E.G., Phillips D.H., Deschodt-Lanckman M.M., Vanherweghem J.L., Nortier J.L. Early proximal tubule injury in experimental aristolochic acid nephropathy: functional and histological studies. Nephrol. Dial. Transplant. 2005, 20:2321-2332.
21. Li J., Zhang L., Jiang Z., Shu B., Li F., Bao Q. Toxicities of aristolochic acid I and aristololactam I in cultured renal epithelial cells. Toxicol. In Vitro 2010, 24:1092-1097.
22. Li X., Wang H. Aristolochic acid nephropathy: what we know and what we have to do. Nephrology (Carlton) 2004, 9:109-111.
23. Lin L.L., Wartmann M., Lin A.Y., Knopf J.L., Seth A., Davis R.J. cPLA2 is phosphorylated and activated by MAP kinase. Cell 1993, 72:269-278.
24. Liu S.P., Sa C., Hu X.L., Kong L. Fluorescence quenching method for the determination of sodium carboxymethyl cellulose with acridine yellow or acridine orange. Spectrochim. Acta A Mol. Biomol. Spectrosc. 2006, 64:817-822.
25. Mengs U. Acute toxicity of aristolochic acid in rodents. Arch. Toxicol. 1987, 59:328-331.
26. Moreno J.J. Effect of aristolochic acid on arachidonic acid cascade and in vivo models of inflammation. Immunopharmacology 1993, 26:1-9.
27. Murphy R.C., Gijon M.A. Biosynthesis and metabolism of leukotrienes. Biochem. J. 2007, 405:379-395.
28. Perico N., Pasini M., Gaspari F., Abbate M., Remuzzi G. Co-participation of thromboxane A2 and leukotriene C4 and D4 in mediating cyclosporine-induced acute renal failure. Transplantation 1991, 52:873-878.
29. Petric R., Nicholson D.W., Ford-Hutchinson A.W. Renal leukotriene C4 synthase: characterization, partial purification and alterations in experimental glomerulonephritis. Biochim. Biophys. Acta 1995, 1254:207-215.
30. Pozdzik A.A., Salmon I.J., Debelle F.D., Decaestecker C., Van den Branden C., Verbeelen D., Deschodt-Lanckman M.M., Vanherweghem J.L., Nortier J.L. Aristolochic acid induces proximal tubule apoptosis and epithelial to mesenchymal transformation. Kidney Int. 2008, 73:595-607.
31. Pozdzik A.A., Salmon I.J., Husson C.P., Decaestecker C., Rogier E., Bourgeade M.F., Deschodt-Lanckman M.M., Vanherweghem J.L., Nortier J.L. Patterns of interstitial inflammation during the evolution of renal injury in experimental aristolochic acid nephropathy. Nephrol. Dial. Transplant. 2008, 23:2480-2491.
32. Qi X., Cai Y., Gong L., Liu L., Chen F., Xiao Y., Wu X., Li Y., Xue X., Ren J. Role of mitochondrial permeability transition in human renal tubular epithelial cell death induced by aristolochic acid. Toxicol. Appl. Pharmacol. 2007, 222:105-110.
33. Shibutani S., Dong H., Suzuki N., Ueda S., Miller F., Grollman A.P. Selective toxicity of aristolochic acids I and II. Drug Metab. Dispos. 2007, 35:1217-1222.
34. Siering H., Abendroth K. Experimental studies on the effect of aristolochic acid in immunosuppressive therapy. Z. Gesamte Inn. Med. 1969, 24(Suppl):155-156.
35. Su Z., Xu S., Zheng F., Li Y. Aristolochic acid induced transdifferentiation and apoptosis in human tubular epithelial cells in vitro. Zhonghua Yu Fang Yi Xue Za Zhi 2002, 36:301-304.
36. Sun D., Feng J., Dai C., Sun L., Jin T., Ma J., Wang L. Role of peritubular capillary loss and hypoxia in progressive tubulointerstitial fibrosis in a rat model of aristolochic acid nephropathy. Am. J. Nephrol. 2006, 26:363-371.
37. Szilagyi G., Simon L., Koska P., Telek G., Nagy Z. Visualization of mitochondrial membrane potential and reactive oxygen species via double staining. Neurosci. Lett. 2006, 399:206-209.
38. Wang H.L., Zhang J.Y. Aristolochic acid induces renal tubular injury and inhibits expression of bone morphogenetic protein-7 mRNA in renal tissue of rats. Zhong Xi Yi Jie He Xue Bao 2008, 6:501-507.
39. Werz O., Steinhilber D. Therapeutic options for 5-lipoxygenase inhibitors. Pharmacol. Ther. 2006, 112:701-718.
40. Witkowicz J. Aristolochic acid nephropathy. Przegl. Lek. 2009, 66:253-256.
41. Yang L., Li X., Wang H. Possible mechanisms explaining the tendency towards interstitial fibrosis in aristolochic acid-induced acute tubular necrosis. Nephrol. Dial. Transplant. 2007, 22:445-456.
42. Zhou H., Das S., Murthy K.S. Erk1/2- and p38 MAP kinase-dependent phosphorylation and activation of cPLA2 by m3 and m2 receptors. Am. J. Physiol. Gastrointest. Liver Physiol. 2003, 284:G472-480.
43. Zhou L., Fu P., Huang X.R., Liu F., Lai K.N., Lan H.Y. Activation of p53 promotes renal injury in acute aristolochic acid nephropathy. J. Am. Soc. Nephrol. 2010, 21:31-41.
44. Zhou S.J., Du G.Y., Zhao Y., Cui H.F., Wang X.R., Li L., Xiao Y.Q. Study on transdifferentiation of renal tubular cells in rat chronic renal interstitial fibrosis induced by Radix Aristolochiae Fangchi Extract. Zhongguo Zhong Yao Za Zhi 2006, 31:1882-1885.